SYS6026 / CSPC Pharma - LARVOL DELTA

A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions (clinicaltrials.gov) - P2 | N=175 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P2 trial

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P=N/A | N=186 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New trial • Oncology • Solid Tumor

A Multicenter, Open-Label, Phase I Clinical Study Evaluating the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of SYS6026 as Monotherapy or in Combination for Advanced Solid Tumors (SGO 2026) - No abstract available

Clinical • Metastases • Monotherapy • P1 data • PK/PD data • Oncology • Solid Tumor